AI in Precision Medicine Market by Application (Drug Discovery, Screening, Diagnosis, Stratification, Staging, Prognosis, Therapy Selection, Monitoring, Risk Management), Indication (Cancer, CNS, CVS), Tools (ML, NLP), & End User -Global Forecast to 2030

1 INTRODUCTION 32 1.1 STUDY OBJECTIVES 32 1.2 MARKET DEFINITION 32 1.3 STUDY SCOPE 33 1.3.1 MARKETS COVERED & REGIONAL SCOPE 33 1.3.2 INCLUSIONS & EXCLUSIONS 34 1.3.3 YEARS CONSIDERED 36 1.4 CURRENCY CONSIDERED 36 1.5 STAKEHOLDERS 36 2 RESEARCH METHODOLOGY 38 2.1 RESEARCH DATA 38 2.1.1 SECONDARY DATA 39 2.1.1.1 Key data from secondary sources 40 2.1.2 PRIMARY DATA 40 2.1.2.1 Key data from primary sources 42 2.2 MARKET SIZE ESTIMATION 44 2.3 MARKET SHARE ESTIMATION 47 2.4 DATA TRIANGULATION 48 2.5 RESEARCH ASSUMPTIONS 49 2.6 LIMITATIONS 49 2.6.1 METHODOLOGY-RELATED LIMITATIONS 49 2.6.2 SCOPE-RELATED LIMITATIONS 49 2.7 RISK ASSESSMENT 50 3 EXECUTIVE SUMMARY 51 4 PREMIUM INSIGHTS 57 4.1 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET OVERVIEW 57 4.2 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY REGION 58 4.3 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER & REGION 59 4.4 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: GEOGRAPHIC SNAPSHOT 60 4.5 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: DEVELOPED VS. EMERGING MARKETS 60   5 MARKET OVERVIEW 61 5.1 INTRODUCTION 61 5.2 MARKET DYNAMICS 61 5.3 MARKET DYNAMICS 62 5.3.1 DRIVERS 62 5.3.1.1 Increase in investments in R&D and rise in demand for personalized medication 62 5.3.1.2 Advancements in genomic research and data availability 64 5.3.1.3 Growth in cross-industry collaborations and partnerships 64 5.3.1.4 Role of regulatory landscape in driving AI adoption in healthcare 66 5.3.2 RESTRAINTS 68 5.3.2.1 Increase in data breach concerns 68 5.3.2.2 High cost of implementation of precision medicine solutions 70 5.3.2.3 Accuracy challenges in AI adoption for healthcare 71 5.3.3 OPPORTUNITIES 71 5.3.3.1 Role of predictive analytics in advancing AI for healthcare 71 5.3.3.2 Leveraging research pipelines and new drug development for AI in healthcare 72 5.3.4 CHALLENGES 73 5.3.4.1 Impact of fairness and bias on AI in healthcare 73 5.3.4.2 Interoperability challenges due to complexity of AI solutions 74 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES 74 5.5 INDUSTRY TRENDS 75 5.5.1 AI'S GROWING ROLE IN PATIENT-SPECIFIC DATA INTEGRATION AND ANALYSIS 75 5.5.2 ADVANCEMENTS IN AI-POWERED PREDICTIVE ANALYTICS FOR TREATMENT OPTIMIZATION 76 5.6 ECOSYSTEM ANALYSIS 76 5.7 VALUE CHAIN ANALYSIS 79 5.8 TECHNOLOGY ANALYSIS 80 5.8.1 KEY TECHNOLOGIES 80 5.8.1.1 Predictive analytics 80 5.8.1.2 Neural networks 81 5.8.1.3 Knowledge graphs 81 5.8.1.4 Cell and gene therapies 81 5.8.1.5 AI-driven single-cell analysis 82 5.8.2 COMPLEMENTARY TECHNOLOGY 82 5.8.2.1 High-performance computing (HPC) 82 5.8.2.2 Next-generation sequencing 82 5.8.2.3 Real-world evidence/Real-world data 83 5.8.2.4 EHR Integration 83 5.8.2.5 Digital health platforms 84   5.8.3 ADJACENT TECHNOLOGIES 84 5.8.3.1 Cloud computing 84 5.8.3.2 Blockchain technology 84 5.8.3.3 Internet of Things (IoT) and wearables 85 5.8.3.4 Robotics and automation 85 5.8.3.5 3D printing for personalized implants and devices 85 5.9 REGULATORY ANALYSIS 86 5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86 5.9.2 REGULATORY SCENARIO 89 5.10 PRICING ANALYSIS 93 5.10.1 INDICATIVE PRICING FOR KEY PLAYERS 93 5.10.2 INDICATIVE PRICE OF KEY COMPONENTS, BY REGION 94 5.11 PORTER’S FIVE FORCES ANALYSIS 95 5.11.1 THREAT OF NEW ENTRANTS 96 5.11.2 THREAT OF SUBSTITUTES 96 5.11.3 BARGAINING POWER OF SUPPLIERS 96 5.11.4 BARGAINING POWER OF BUYERS 97 5.11.5 INTENSITY OF COMPETITIVE RIVALRY 97 5.12 PATENT ANALYSIS 97 5.12.1 PATENT PUBLICATION TRENDS 97 5.12.2 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR AI IN PRECISION MEDICINE 98 5.12.3 KEY PATENTS IN AI IN PRECISION MEDICINE MARKET 99 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 102 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 102 5.13.2 KEY BUYING CRITERIA 103 5.14 END-USER ANALYSIS 104 5.14.1 UNMET NEEDS 104 5.14.2 END-USER EXPECTATIONS 105 5.15 KEY CONFERENCES & EVENTS 106 5.16 CASE STUDY ANALYSIS 107 5.16.1 SANOFI LEVERAGED AI-DRIVEN PRECISION MEDICINE TO IDENTIFY PATIENT SUBTYPES AND NOVEL TARGETS IN INFLAMMATORY BOWEL DISEASE 107 5.16.2 IBM’S AI-DRIVEN SOLUTION IMPROVED CLINICAL TRIAL ENROLLMENT AT MAYO CLINIC BY ENHANCING PATIENT MATCHING 108 5.16.3 ENHANCING PATIENT IDENTIFICATION FOR RARE ONCOLOGY BIOMARKERS THROUGH GENOMIC TESTING AND STRATEGIC COLLABORATION 108 5.17 INVESTMENT AND FUNDING SCENARIO 109 5.18 BUSINESS MODELS 109 5.19 IMPACT OF AI/GEN AI IN PRECISION MEDICINE MARKET 111 5.19.1 KEY USE CASES 112 5.19.2 CASE STUDIES OF AI/GENERATIVE AI IMPLEMENTATION 112 5.19.2.1 Enhancing patient outcomes with AI-driven predictive analytics at Johns Hopkins Hospital 112 5.19.3 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 113 5.19.3.1 AI in drug discovery market 113 5.19.3.2 Genomics market 113 5.19.3.3 Artificial intelligence market 114 5.19.3.4 Pharmacogenomics market 114 5.19.4 USER READINESS AND IMPACT ASSESSMENT 114 5.19.4.1 User readiness 114 5.19.4.1.1 Healthcare providers 114 5.19.4.1.2 Pharmaceutical & biotechnology companies 114 6 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION 115 6.1 INTRODUCTION 116 6.2 DRUG DISCOVERY & DEVELOPMENT 116 6.2.1 DRUG DISCOVERY 117 6.2.2 UNDERSTANDING DISEASES 117 6.2.2.1 Rise in data mining to link targets to diseases 117 6.2.3 DRUG REPURPOSING 118 6.2.3.1 Use of graphs for targeted approach to reduce timelines and costs 118 6.2.4 DE NOVO DRUG DESIGN 119 6.2.4.1 Availability of large-scale biomedical datasets and urgent demand for novel treatments for complex diseases 119 6.2.5 DRUG OPTIMIZATION 120 6.2.5.1 Need to process extensive data on molecular properties, target interactions, and clinical outcomes 120 6.2.6 SAFETY & TOXICITY 121 6.2.6.1 Building generalizable model for toxicity and off-target effect prediction 121 6.2.7 CLINICAL DEVELOPMENT 122 6.2.7.1 Designing and conducting clinical trials for personalized dosing, targeted therapies 122 6.3 DIAGNOSTICS & SCREENING 124 6.3.1 RISK ASSESSMENT & PATIENT STRATIFICATION 124 6.3.1.1 Leveraging AI to personalize treatment plan 124 6.3.2 DISEASE SCREENING 125 6.3.2.1 Leveraging machine learning to peruse and resolve complex patient data 125 6.3.3 DISEASE DIAGNOSIS 126 6.3.3.1 Identifying biomarkers for precise treatment 126 6.3.4 DISEASE PROGRESSION, STAGING, AND PROGNOSIS 127 6.3.4.1 Using AI to track disease conditions 127   6.4 THERAPEUTICS 128 6.4.1 THERAPY SELECTION & PLANNING 129 6.4.1.1 Leveraging generative models to predict and design suitable treatment 129 6.4.2 THERAPY MONITORING 130 6.4.2.1 Need to effectively track safety and efficacy of treatment 130 6.4.3 POST-TREATMENT SURVEILLANCE & FOLLOW-UP 131 6.4.3.1 AI algorithms to identify subtle patterns in data, allowing for early detection of potential issues 131 7 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA 133 7.1 INTRODUCTION 134 7.2 ONCOLOGY 134 7.2.1 HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE CANCER DRUGS 134 7.3 RARE DISEASES 136 7.3.1 COMBATING CHALLENGING THERAPEUTICS DUE TO COMPLEX AND HETEROGENEOUS NATURE OF RARE DISEASES 136 7.4 INFECTIOUS DISEASES 137 7.4.1 NEED FOR INNOVATION IN INFECTIOUS DISEASE TREATMENT, ESPECIALLY AFTER IMPACT OF COVID-19 137 7.5 NEUROLOGY 139 7.5.1 SHORTAGE AND COMPLEXITY OF NEURODEGENERATIVE DISEASES 139 7.6 CARDIOLOGY 141 7.6.1 WIDE RANGE AND INCIDENCE OF CARDIOVASCULAR DISEASES 141 7.7 HEMATOLOGY 142 7.7.1 AI-DRIVEN ALGORITHMS TO ANALYZE BLOOD SAMPLES, IMAGING DATA, AND GENOMIC PROFILES TO DETECT ABNORMALITIES 142 7.8 OTHER THERAPEUTIC AREAS 143 8 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT 145 8.1 INTRODUCTION 146 8.2 SOFTWARE 146 8.2.1 SCALABILITY AND FLEXIBILITY OF AI SOFTWARE TO ENHANCE EFFICIENCY OF CLINICAL WORKFLOWS 146 8.3 SERVICES 148 8.3.1 NEED FOR EXPERT ASSISTANCE AMONG HEALTHCARE ORGANIZATIONS IN ADOPTING AND OPTIMIZING AI TECHNOLOGIES 148   9 AI IN PRECISION MEDICINE MARKET, BY TOOL 150 9.1 INTRODUCTION 151 9.2 MACHINE LEARNING 151 9.2.1 DEEP LEARNING 153 9.2.1.1 Convolutional neural networks 154 9.2.1.1.1 Interpreting complex biological data to enable personalizing healthcare 154 9.2.1.2 Recurrent neural networks (RNNs) 155 9.2.1.2.1 Optimizing clinical data to model patient trajectories by analyzing longitudinal data 155 9.2.1.3 Generative adversarial networks (GANs) 156 9.2.1.3.1 GAN to focus on new molecules and biological datasets 156 9.2.1.4 Graph neural networks (GNNs) 157 9.2.1.4.1 Predicting drug-drug interactions to optimize personalized treatment 157 9.2.1.5 Other deep learning tools 158 9.2.2 SUPERVISED MACHINE LEARNING 158 9.2.3 REINFORCEMENT MACHINE LEARNING 159 9.2.4 UNSUPERVISED MACHINE LEARNING 160 9.2.5 OTHER MACHINE LEARNING TOOLS 161 9.3 NATURAL LANGUAGE PROCESSING 162 9.3.1 ABUNDANCE OF UNSTRUCTURED DATA IN CLINICAL RESEARCH TO BE INTERPRETED 162 9.4 CONTEXT-AWARE PROCESSING & COMPUTING 163 9.4.1 TAILORING PATIENT CARE IN REAL TIME TO ENHANCE PRECISION MEDICINE 163 9.5 COMPUTER VISION 164 9.5.1 INCREASE IN USE OF IMAGING BIOMARKERS TO SUPPORT SURGICAL PRECISION 164 9.6 IMAGE ANALYSIS 165 9.6.1 HARNESSING MACHINE LEARNING TO AUTOMATE TECHNIQUES SUCH AS QUANTITATIVE IMAGING AND RADIOMICS 165 9.7 OTHER TOOLS 166 10 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT 168 10.1 INTRODUCTION 169 10.2 CLOUD-BASED MODEL 169 10.2.1 RESEARCH COLLABORATION AND COST-EFFICIENCY OF CLOUD DEPLOYMENT 169 10.3 ON-PREMISE MODEL 171 10.3.1 EASIER TO SECURE PATIENT DATA AND ENSURE COMPLIANCE IN ON-PREMISE AI-DRIVEN PRECISION MEDICINE 171 10.4 HYBRID MODEL 172 10.4.1 HYBRID MODELS TO ENHANCE FLEXIBILITY AND SECURITY 172 11 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER 174 11.1 INTRODUCTION 175 11.2 HEALTHCARE PROVIDERS 175 11.2.1 REVOLUTIONIZING PATIENT CARE AND TREATMENT DELIVERY THROUGH ADVANCED TECHNOLOGIES 175 11.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 176 11.3.1 DRIVING DRUG DEVELOPMENT EFFICIENCY TO DESIGN ADAPTIVE TRIAL PROTOCOLS AND OPTIMIZE TREATMENT 176 11.4 MEDICAL DEVICE & EQUIPMENT COMPANIES 177 11.4.1 INTEGRATION OF AI IN MEDICAL DEVICES TO ENHANCE PRECISION AND PERSONALIZED HEALTHCARE 177 11.5 RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS 178 11.5.1 AI IN ACADEMIC INSTITUTES AND PUBLIC SECTOR COLLABORATIONS TO ACCELERATE INNOVATION AND RESEARCH 178 11.6 OTHER END USERS 179 12 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY REGION 181 12.1 INTRODUCTION 182 12.2 NORTH AMERICA 182 12.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 183 12.2.2 US 187 12.2.2.1 US to dominate North American market with advanced regulatory system 187 12.2.3 CANADA 190 12.2.3.1 Emergence of new AI-based startups and high health expenditure 190 12.3 EUROPE 194 12.3.1 EUROPE: MACROECONOMIC OUTLOOK 194 12.3.2 UK 198 12.3.2.1 Favorable government R&D investment and collaborations focused on drug discovery 198 12.3.3 GERMANY 201 12.3.3.1 Growing R&D investment by pharma and biotech companies 201 12.3.4 FRANCE 204 12.3.4.1 Strong government support through investments in initiatives 204 12.3.5 ITALY 208 12.3.5.1 Government Initiatives addressing local healthcare challenges through studies aimed at broader precision medicine strategies 208 12.3.6 SPAIN 211 12.3.6.1 High investments by pharmaceutical companies 211 12.3.7 REST OF EUROPE 214 12.4 ASIA PACIFIC 217 12.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK 217 12.4.2 JAPAN 222 12.4.2.1 High investment in R&D and government initiatives focused on treatment outcomes 222 12.4.3 CHINA 226 12.4.3.1 Government funding to advance data analysis and international collaborations to develop targeted therapies 226 12.4.4 INDIA 229 12.4.4.1 High growth of pharmaceutical and medical device industries 229 12.4.5 REST OF ASIA PACIFIC 233 12.5 LATIN AMERICA 236 12.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK 236 12.5.2 BRAZIL 240 12.5.2.1 Increase in governmental support through initiatives such as Brazilian Artificial Intelligence Plan 240 12.5.3 MEXICO 243 12.5.3.1 High potential to become leader in terms of readiness in technology 243 12.5.4 REST OF LATIN AMERICA 246 12.6 MIDDLE EAST & AFRICA 249 12.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 249 12.6.2 GCC COUNTRIES 253 12.6.2.1 Increasing emphasis on personalized medicines and developing healthcare infrastructure 253 12.6.3 REST OF MIDDLE EAST & AFRICA 257 13 COMPETITIVE LANDSCAPE 261 13.1 INTRODUCTION 261 13.2 KEY PLAYER STRATEGY/RIGHT TO WIN 261 13.3 REVENUE ANALYSIS, 2019–2023 264 13.4 MARKET SHARE ANALYSIS, 2023 265 13.4.1 RANKING OF KEY MARKET PLAYERS 267 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 268 13.5.1 STARS 268 13.5.2 EMERGING LEADERS 268 13.5.3 PERVASIVE PLAYERS 268 13.5.4 PARTICIPANTS 268 13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 270 13.5.5.1 Company footprint 270 13.5.5.2 Therapeutic area footprint 271 13.5.5.3 End user footprint 272 13.5.5.4 Component footprint 273 13.5.5.5 Deployment footprint 274 13.5.5.6 Region footprint 275   13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 276 13.6.1 PROGRESSIVE COMPANIES 276 13.6.2 RESPONSIVE COMPANIES 276 13.6.3 DYNAMIC COMPANIES 276 13.6.4 STARTING BLOCKS 276 13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 278 13.6.5.1 Detailed list of key startup/SME players 278 13.6.5.2 Competitive benchmarking of key emerging players/startups, by region 279 13.7 COMPANY VALUATION AND FINANCIAL METRICS 279 13.7.1 COMPANY VALUATION 279 13.7.2 FINANCIAL METRICS 280 13.8 BRAND/PRODUCT COMPARISON 281 13.9 COMPETITIVE SCENARIO 282 13.9.1 PRODUCT LAUNCHES 282 13.9.2 DEALS 283 13.9.3 EXPANSIONS 285 13.9.4 OTHER DEVELOPMENTS 286 14 COMPANY PROFILES 287 14.1 KEY PLAYERS 287 14.1.1 NVIDIA CORPORATION 287 14.1.1.1 Business overview 287 14.1.1.2 Products/Services/Solutions offered 289 14.1.1.3 Recent developments 289 14.1.1.3.1 Product launches 289 14.1.1.3.2 Deals 291 14.1.1.4 MnM view 295 14.1.1.4.1 Right to win 295 14.1.1.4.2 Strategic choices 295 14.1.1.4.3 Weaknesses & competitive threats 295 14.1.2 EXSCIENTIA 296 14.1.2.1 Business overview 296 14.1.2.2 Products/Services/Solutions offered 297 14.1.2.3 Recent developments 298 14.1.2.3.1 Product launches 298 14.1.2.3.2 Deals 298 14.1.2.3.3 Expansions 303 14.1.2.3.4 Other developments 304 14.1.2.4 MnM view 305 14.1.2.4.1 Right to win 305 14.1.2.4.2 Strategic choices 305 14.1.2.4.3 Weaknesses and competitive threats 306 14.1.3 GOOGLE 307 14.1.3.1 Business overview 307 14.1.3.2 Products/Services/Solutions offered 309 14.1.3.3 Recent developments 309 14.1.3.3.1 Product launches 309 14.1.3.3.2 Deals 310 14.1.3.3.3 Expansions 311 14.1.3.4 MnM view 311 14.1.3.4.1 Right to win 311 14.1.3.4.2 Strategic choices 311 14.1.3.4.3 Weaknesses and competitive threats 312 14.1.4 ILLUMINA, INC. 313 14.1.4.1 Business overview 313 14.1.4.2 Products/Services/Solutions offered 314 14.1.4.3 Recent developments 315 14.1.4.3.1 Product launches 315 14.1.4.3.2 Deals 316 14.1.4.4 MnM view 317 14.1.4.4.1 Right to win 317 14.1.4.4.2 Strategic choices 317 14.1.4.4.3 Weaknesses and competitive threats 317 14.1.5 TEMPUS AI, INC. 318 14.1.5.1 Business overview 318 14.1.5.2 Products/Services/Solutions offered 318 14.1.5.3 Recent developments 319 14.1.5.3.1 Product launches 319 14.1.5.3.2 Deals 320 14.1.5.3.3 Expansions 323 14.1.5.3.4 Other developments 324 14.1.5.4 MnM view 324 14.1.5.4.1 Right to win 324 14.1.5.4.2 Strategic choices 324 14.1.5.4.3 Weaknesses and competitive threats 324 14.1.6 BENEVOLENTAI 325 14.1.6.1 Business overview 325 14.1.6.2 Products/Services/Solutions offered 326 14.1.6.3 Recent developments 326 14.1.6.3.1 Deals 326 14.1.7 MICROSOFT CORPORATION 329 14.1.7.1 Business overview 329 14.1.7.2 Products/Services/Solutions offered 331 14.1.7.3 Recent developments 331 14.1.7.3.1 Deals 331 14.1.8 IBM 334 14.1.8.1 Business overview 334 14.1.8.2 Products/Services/Solutions offered 336 14.1.8.3 Recent developments 336 14.1.8.3.1 Deals 336 14.1.9 GE HEALTHCARE 337 14.1.9.1 Business overview 337 14.1.9.2 Products/Services/Solutions offered 338 14.1.9.3 Recent developments 339 14.1.9.3.1 Product launches 339 14.1.9.3.2 Deals 340 14.1.9.3.3 Other developments 341 14.1.10 DEEP GENOMICS 342 14.1.10.1 Business overview 342 14.1.10.2 Products/Services/Solutions offered 342 14.1.10.3 Recent developments 343 14.1.10.3.1 Product launches 343 14.1.10.3.2 Deals 343 14.1.10.3.3 Other developments 343 14.1.11 SIEMENS HEALTHINEERS AG 344 14.1.11.1 Business overview 344 14.1.11.2 Products/Solutions/Services offered 345 14.1.11.3 Recent developments 346 14.1.11.3.1 Deals 346 14.1.12 BIOXCEL THERAPEUTICS, INC. 347 14.1.12.1 Business overview 347 14.1.12.2 Products/Solutions/Services offered 347 14.1.12.3 Recent developments 348 14.1.12.3.1 Deals 348 14.1.12.3.2 Other developments 348 14.1.13 INSILICO MEDICINE 349 14.1.13.1 Business overview 349 14.1.13.2 Products/Services/Solutions offered 350 14.1.13.3 Recent developments 350 14.1.13.3.1 Product launches 350 14.1.13.3.2 Deals 352 14.1.13.3.3 Other developments 356 14.1.14 PATHAI, INC. 358 14.1.14.1 Business overview 358 14.1.14.2 Products/Services/Solutions offered 359 14.1.14.3 Recent developments 360 14.1.14.3.1 Product launches 360 14.1.14.3.2 Deals 362 14.1.14.3.3 Other developments 364 14.1.15 VERGE GENOMICS 365 14.1.15.1 Business overview 365 14.1.15.2 Products/Services/Solutions offered 365 14.1.15.3 Recent developments 366 14.1.15.3.1 Deals 366 14.1.16 GUARDANT HEALTH, INC. 367 14.1.16.1 Business overview 367 14.1.16.2 Products/Services/Solutions offered 368 14.1.16.3 Recent developments 369 14.1.16.3.1 Product launches 369 14.1.16.3.2 Deals 370 14.1.16.3.3 Other developments 372 14.1.17 GRAIL, INC. 374 14.1.17.1 Business overview 374 14.1.17.2 Products/Services/Solutions offered 374 14.1.17.3 Recent developments 375 14.1.17.3.1 Deals 375 14.1.18 FOUNDATION MEDICINE, INC. 377 14.1.18.1 Business overview 377 14.1.18.2 Products/Services/Solutions offered 377 14.1.18.3 Recent developments 378 14.1.18.3.1 Deals 378 14.1.18.3.2 Other developments 380 14.1.19 PROSCIA INC. 382 14.1.19.1 Business overview 382 14.1.19.2 Products/Services/Solutions offered 382 14.1.19.3 Recent developments 383 14.1.19.3.1 Product launches 383 14.1.19.3.2 Deals 383 14.1.19.3.3 Other developments 384 14.1.20 FLATIRON HEALTH 385 14.1.20.1 Business overview 385 14.1.20.2 Products/Services/Solutions offered 385 14.1.20.3 Recent developments 386 14.1.20.3.1 Deals 386 14.1.20.3.2 Other developments 387   14.2 OTHER PLAYERS 388 14.2.1 PREDICTIVE ONCOLOGY 388 14.2.2 PAIGE AI, INC. 389 14.2.3 DENSITAS INC. 390 14.2.4 ZEPHYR AI, INC. 391 14.2.5 NUCLEAI, INC. 392 15 APPENDIX 393 15.1 DISCUSSION GUIDE 393 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 399 15.3 CUSTOMIZATION OPTIONS 401 15.4 RELATED REPORTS 401 15.5 AUTHOR DETAILS 402

TABLE 1 AI IN PRECISION MEDICINE MARKET: INCLUSIONS & EXCLUSIONS 34 TABLE 2 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET DYNAMICS: IMPACT ANALYSIS 62 TABLE 3 INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS, 2021–2024 65 TABLE 4 BIGGEST HEALTHCARE SECURITY BREACHES, 2023 70 TABLE 5 AI IN DRUG DISCOVERY MARKET: ROLE IN ECOSYSTEM 78 TABLE 6 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86 TABLE 7 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87 TABLE 9 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88 TABLE 10 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88 TABLE 11 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88 TABLE 12 NORTH AMERICA: REGULATORY SCENARIO 89 TABLE 13 EUROPE: REGULATORY SCENARIO 90 TABLE 14 ASIA PACIFIC: REGULATORY SCENARIO 91 TABLE 15 MIDDLE EAST & AFRICA: REGULATORY SCENARIO 92 TABLE 16 LATIN AMERICA: REGULATORY SCENARIO 92 TABLE 17 INDICATIVE PRICING FOR KEY PLAYERS, 2023 (USD) 93 TABLE 18 INDICATIVE PRICE OF KEY COMPONENTS, BY REGION, 2022–2024 (USD) 94 TABLE 19 AI IN PRECISION MEDICINE MARKET: PORTER’S FIVE FORCES ANALYSIS 96 TABLE 20 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR AI IN PRECISION MEDICINE 98 TABLE 21 AI IN PRECISION MEDICINE MARKET: LIST OF PATENTS/PATENT APPLICATIONS 99 TABLE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS 102 TABLE 23 KEY BUYING CRITERIA FOR TOP THREE END USERS 103 TABLE 24 UNMET NEEDS IN AI IN PRECISION MEDICINE MARKET 104 TABLE 25 END-USER EXPECTATIONS IN AI IN PRECISION MEDICINE MARKET 105 TABLE 26 KEY CONFERENCES & EVENTS, 2024–2025 106 TABLE 27 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 116 TABLE 28 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY APPLICATION, 2022–2030 (USD MILLION) 116 TABLE 29 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR DRUG DISCOVERY, BY APPLICATION, 2022–2030 (USD MILLION) 117 TABLE 30 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR UNDERSTANDING DISEASES, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 118 TABLE 31 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR DRUG REPURPOSING, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 119 TABLE 32 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR DE NOVO DRUG DESIGN, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 120 TABLE 33 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR DRUG OPTIMIZATION, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 121 TABLE 34 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR SAFETY & TOXICITY, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 122 TABLE 35 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR CLINICAL DEVELOPMENT, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 123 TABLE 36 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR DIAGNOSTICS & SCREENING, BY TYPE, 2022–2030 (USD MILLION) 124 TABLE 37 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR RISK ASSESSMENT & PATIENT STRATIFICATION, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 125 TABLE 38 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR DISEASE SCREENING, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 126 TABLE 39 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR DISEASE DIAGNOSIS, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 127 TABLE 40 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR DISEASE PROGRESSION, STAGING, AND PROGNOSIS, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 128 TABLE 41 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR THERAPEUTICS, BY TYPE, 2022–2030 (USD MILLION) 129 TABLE 42 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR THERAPY SELECTION & PLANNING, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 130 TABLE 43 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR THERAPY MONITORING, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 131 TABLE 44 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR POST-TREATMENT SURVEILLANCE & FOLLOW-UP, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 132 TABLE 45 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 134 TABLE 46 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR ONCOLOGY, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 136 TABLE 47 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR RARE DISEASES, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 137 TABLE 48 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR INFECTIOUS DISEASES, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 139 TABLE 49 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 140 TABLE 50 INDICATIVE LIST OF DEVELOPMENTS IN CARDIOLOGY 141 TABLE 51 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR CARDIOLOGY, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 142 TABLE 52 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR HEMATOLOGY, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 143 TABLE 53 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 144 TABLE 54 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022–2030 (USD MILLION) 146 TABLE 55 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR SOFTWARE, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 147 TABLE 56 ARTIFICIAL INTELLIGENCE SERVICES IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 149 TABLE 57 AI IN PRECISION MEDICINE MARKET, BY TOOL, 2022–2030 (USD MILLION) 151 TABLE 58 MACHINE LEARNING IN PRECISION MEDICINE MARKET, BY TYPE, 2022–2030 (USD MILLION) 152 TABLE 59 MACHINE LEARNING IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 152 TABLE 60 DEEP LEARNING IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 153 TABLE 61 CONVOLUTIONAL NEURAL NETWORKS IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 154 TABLE 62 RECURRENT NEURAL NETWORKS IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 155 TABLE 63 GENERATIVE ADVERSARIAL NETWORKS IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 156 TABLE 64 GRAPH NEURAL NETWORKS IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 157 TABLE 65 OTHER DEEP LEARNING TOOLS IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 158 TABLE 66 SUPERVISED LEARNING IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 159 TABLE 67 REINFORCEMENT LEARNING IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 160 TABLE 68 UNSUPERVISED LEARNING IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 161 TABLE 69 OTHER MACHINE LEARNING TOOLS IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 162 TABLE 70 NATURAL LANGUAGE PROCESSING IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 163 TABLE 71 CONTEXT-AWARE PROCESSING & COMPUTING IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 164 TABLE 72 COMPUTER VISION AI IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 165 TABLE 73 IMAGE ANALYSIS IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 166 TABLE 74 OTHER AI TOOLS IN PRECISION MEDICINE MARKET, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 167 TABLE 75 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022–2030 (USD MILLION) 169 TABLE 76 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR CLOUD-BASED MODEL, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 171 TABLE 77 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR ON-PREMISE MODEL, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 172 TABLE 78 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR HYBRID MODEL, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 173 TABLE 79 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022–2030 (USD MILLION) 175 TABLE 80 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR HEALTHCARE PROVIDERS, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 176 TABLE 81 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 177 TABLE 82 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR MEDICAL DEVICE & EQUIPMENT COMPANIES, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 178 TABLE 83 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 179 TABLE 84 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET FOR OTHER END USERS, BY COUNTRY/REGION, 2022–2030 (USD MILLION) 180 TABLE 85 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY REGION, 2022–2030 (USD MILLION) 182 TABLE 86 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 184 TABLE 87 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 184 TABLE 88 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 185 TABLE 89 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022–2030 (USD MILLION) 185 TABLE 90 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022–2030 (USD MILLION) 186 TABLE 91 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT 2022–2030 (USD MILLION) 186 TABLE 92 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022–2030 (USD MILLION) 187 TABLE 93 US: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 188 TABLE 94 US: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 188 TABLE 95 US: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022–2030 (USD MILLION) 189 TABLE 96 US: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022–2030 (USD MILLION) 189 TABLE 97 US: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT 2022–2030 (USD MILLION) 189 TABLE 98 US: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022–2030 (USD MILLION) 190 TABLE 99 CANADA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 191 TABLE 100 CANADA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 191 TABLE 101 CANADA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022–2030 (USD MILLION) 192 TABLE 102 CANADA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022–2030 (USD MILLION) 192 TABLE 103 CANADA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT 2022–2030 (USD MILLION) 193 TABLE 104 CANADA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022–2030 (USD MILLION) 193 TABLE 105 EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 195 TABLE 106 EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 195 TABLE 107 EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 196 TABLE 108 EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022–2030 (USD MILLION) 196 TABLE 109 EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022–2030 (USD MILLION) 197 TABLE 110 EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022–2030 (USD MILLION) 197 TABLE 111 EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022–2030 (USD MILLION) 198 TABLE 112 UK: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 199 TABLE 113 UK: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 199 TABLE 114 UK: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022–2030 (USD MILLION) 200 TABLE 115 UK: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022–2030 (USD MILLION) 200 TABLE 116 UK: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022–2030 (USD MILLION) 200 TABLE 117 UK: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022–2030 (USD MILLION) 201 TABLE 118 GERMANY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 202 TABLE 119 GERMANY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 202 TABLE 120 GERMANY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022–2030 (USD MILLION) 203 TABLE 121 GERMANY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022–2030 (USD MILLION) 203 TABLE 122 GERMANY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022–2030 (USD MILLION) 204 TABLE 123 GERMANY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022–2030 (USD MILLION) 204 TABLE 124 FRANCE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 205 TABLE 125 FRANCE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 205 TABLE 126 FRANCE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022–2030 (USD MILLION) 206 TABLE 127 FRANCE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022–2030 (USD MILLION) 206 TABLE 128 FRANCE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022–2030 (USD MILLION) 207 TABLE 129 FRANCE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022–2030 (USD MILLION) 207 TABLE 130 ITALY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 208 TABLE 131 ITALY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 209 TABLE 132 ITALY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022–2030 (USD MILLION) 209 TABLE 133 ITALY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022–2030 (USD MILLION) 210 TABLE 134 ITALY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022–2030 (USD MILLION) 210 TABLE 135 ITALY: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022–2030 (USD MILLION) 211 TABLE 136 SPAIN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 212 TABLE 137 SPAIN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 212 TABLE 138 SPAIN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022–2030 (USD MILLION) 213 TABLE 139 SPAIN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022–2030 (USD MILLION) 213 TABLE 140 SPAIN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022–2030 (USD MILLION) 213 TABLE 141 SPAIN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022–2030 (USD MILLION) 214 TABLE 142 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 214 TABLE 143 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 215 TABLE 144 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022–2030 (USD MILLION) 215 TABLE 145 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022–2030 (USD MILLION) 216 TABLE 146 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022–2030 (USD MILLION) 216 TABLE 147 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022–2030 (USD MILLION) 217 TABLE 148 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 219 TABLE 149 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 219 TABLE 150 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 220 TABLE 151 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022–2030 (USD MILLION) 220 TABLE 152 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022–2030 (USD MILLION) 221 TABLE 153 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022–2030 (USD MILLION) 221 TABLE 154 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022–2030 (USD MILLION) 222 TABLE 155 JAPAN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 223 TABLE 156 JAPAN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 223 TABLE 157 JAPAN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022–2030 (USD MILLION) 224 TABLE 158 JAPAN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022–2030 (USD MILLION) 224 TABLE 159 JAPAN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022–2030 (USD MILLION) 225 TABLE 160 JAPAN: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022–2030 (USD MILLION) 225 TABLE 161 CHINA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 226 TABLE 162 CHINA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 227 TABLE 163 CHINA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022–2030 (USD MILLION) 227 TABLE 164 CHINA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022–2030 (USD MILLION) 228 TABLE 165 CHINA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022–2030 (USD MILLION) 228 TABLE 166 CHINA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022–2030 (USD MILLION) 229 TABLE 167 INDIA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 230 TABLE 168 INDIA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 230 TABLE 169 INDIA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022–2030 (USD MILLION) 231 TABLE 170 INDIA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022–2030 (USD MILLION) 231 TABLE 171 INDIA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022–2030 (USD MILLION) 232 TABLE 172 INDIA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022–2030 (USD MILLION) 232 TABLE 173 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 233 TABLE 174 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 234 TABLE 175 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022–2030 (USD MILLION) 234 TABLE 176 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022–2030 (USD MILLION) 235 TABLE 177 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022–2030 (USD MILLION) 235 TABLE 178 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022–2030 (USD MILLION) 236 TABLE 179 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY REGION, 2022–2030 (USD MILLION) 237 TABLE 180 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 237 TABLE 181 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 238 TABLE 182 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022–2030 (USD MILLION) 238 TABLE 183 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022–2030 (USD MILLION) 239 TABLE 184 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022–2030 (USD MILLION) 239 TABLE 185 LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022–2030 (USD MILLION) 240 TABLE 186 BRAZIL: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 241 TABLE 187 BRAZIL: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 241 TABLE 188 BRAZIL: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022–2030 (USD MILLION) 242 TABLE 189 BRAZIL: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022–2030 (USD MILLION) 242 TABLE 190 BRAZIL: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022–2030 (USD MILLION) 242 TABLE 191 BRAZIL: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022–2030 (USD MILLION) 243 TABLE 192 MEXICO: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 244 TABLE 193 MEXICO: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 244 TABLE 194 MEXICO: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022–2030 (USD MILLION) 245 TABLE 195 MEXICO: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022–2030 (USD MILLION) 245 TABLE 196 MEXICO: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022–2030 (USD MILLION) 245 TABLE 197 MEXICO: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022–2030 (USD MILLION) 246 TABLE 198 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 246 TABLE 199 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 247 TABLE 200 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022–2030 (USD MILLION) 247 TABLE 201 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022–2030 (USD MILLION) 248 TABLE 202 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022–2030 (USD MILLION) 248 TABLE 203 REST OF LATIN AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022–2030 (USD MILLION) 249 TABLE 204 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY REGION, 2022–2030 (USD MILLION) 250 TABLE 205 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 250 TABLE 206 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 251 TABLE 207 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022–2030 (USD MILLION) 251 TABLE 208 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022–2030 (USD MILLION) 252 TABLE 209 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022–2030 (USD MILLION) 252 TABLE 210 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022–2030 (USD MILLION) 253 TABLE 211 GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 254 TABLE 212 GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 254 TABLE 213 GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022–2030 (USD MILLION) 255 TABLE 214 GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022–2030 (USD MILLION) 255 TABLE 215 GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022–2030 (USD MILLION) 256 TABLE 216 GCC COUNTRIES: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022–2030 (USD MILLION) 256 TABLE 217 REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 257 TABLE 218 REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2022–2030 (USD MILLION) 258 TABLE 219 REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2022–2030 (USD MILLION) 258 TABLE 220 REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2022–2030 (USD MILLION) 259 TABLE 221 REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2022–2030 (USD MILLION) 259 TABLE 222 REST OF MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022–2030 (USD MILLION) 260 TABLE 223 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN AI PRECISION MEDICINE MARKET, JANUARY 2021–OCTOBER 2024 261 TABLE 224 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: DEGREE OF COMPETITION 265 TABLE 225 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: THERAPEUTIC AREA FOOTPRINT, 2023 271 TABLE 226 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: END USER FOOTPRINT, 2023 272 TABLE 227 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: COMPONENT FOOTPRINT, 2023 273 TABLE 228 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: DEPLOYMENT FOOTPRINT, 2023 274 TABLE 229 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: REGION FOOTPRINT, 2023 275 TABLE 230 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS, 2023 278 TABLE 231 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY REGION, 2023 279 TABLE 232 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: PRODUCT LAUNCHES, JANUARY 2021–OCTOBER 2024 282 TABLE 233 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: DEALS, J ANUARY 2021–OCTOBER 2024 283 TABLE 234 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: EXPANSIONS, JANUARY 2021–OCTOBER 2024 285 TABLE 235 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024 286 TABLE 236 NVIDIA CORPORATION: COMPANY OVERVIEW 287 TABLE 237 NVIDIA CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED 289 TABLE 238 NVIDIA CORPORATION: PRODUCT LAUNCHES 289 TABLE 239 NVIDIA CORPORATION: DEALS 291 TABLE 240 EXSCIENTIA: COMPANY OVERVIEW 296 TABLE 241 EXSCIENTIA: PRODUCTS/SERVICES/SOLUTIONS OFFERED 297 TABLE 242 EXSCIENTIA: PRODUCT LAUNCHES 298 TABLE 243 EXSCIENTIA: DEALS 298 TABLE 244 EXSCIENTIA: EXPANSIONS 303 TABLE 245 EXSCIENTIA: OTHER DEVELOPMENTS 304 TABLE 246 GOOGLE: COMPANY OVERVIEW 307 TABLE 247 GOOGLE: PRODUCTS/SERVICES/SOLUTIONS OFFERED 309 TABLE 248 GOOGLE: PRODUCT LAUNCHES 309 TABLE 249 GOOGLE: DEALS 310 TABLE 250 GOOGLE: EXPANSIONS 311 TABLE 251 ILLUMINA, INC.: COMPANY OVERVIEW 313 TABLE 252 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 314 TABLE 253 ILLUMINA, INC.: PRODUCT LAUNCHES 315 TABLE 254 ILLUMINA, INC.: DEALS 316 TABLE 255 TEMPUS: COMPANY OVERVIEW 318 TABLE 256 TEMPUS: PRODUCTS/SERVICES/SOLUTIONS OFFERED 318 TABLE 257 TEMPUS: PRODUCT LAUNCHES 319 TABLE 258 TEMPUS: DEALS 320 TABLE 259 TEMPUS: EXPANSIONS 323 TABLE 260 TEMPUS: OTHER DEVELOPMENTS 324 TABLE 261 BENEVOLENTAI: COMPANY OVERVIEW 325 TABLE 262 BENEVOLENTAI: PRODUCTS/SERVICES/SOLUTIONS OFFERED 326 TABLE 263 BENEVOLENTAI: DEALS 326 TABLE 264 MICROSOFT CORPORATION: COMPANY OVERVIEW 329 TABLE 265 MICROSOFT CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED 331 TABLE 266 MICROSOFT CORPORATION: DEALS 331 TABLE 267 IBM: COMPANY OVERVIEW 334 TABLE 268 IBM: PRODUCTS/SERVICES/SOLUTIONS OFFERED 336 TABLE 269 IBM: DEALS 336 TABLE 270 GE HEALTHCARE: COMPANY OVERVIEW 337 TABLE 271 GE HEALTHCARE: PRODUCTS/SERVICES/SOLUTIONS OFFERED 338 TABLE 272 GE HEALTHCARE: PRODUCT LAUNCHES 339 TABLE 273 GE HEALTHCARE: DEALS 340 TABLE 274 GE HEALTHCARE: OTHER DEVELOPMENTS 341 TABLE 275 DEEP GENOMICS: COMPANY OVERVIEW 342 TABLE 276 DEEP GENOMICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED 342 TABLE 277 DEEP GENOMICS: PRODUCT LAUNCHES 343 TABLE 278 DEEP GENOMICS: DEALS 343 TABLE 279 DEEP GENOMICS: OTHER DEVELOPMENTS 343 TABLE 280 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 344 TABLE 281 SIEMENS HEALTHINEERS AG: PRODUCTS/SOLUTIONS/SERVICES OFFERED 345 TABLE 282 SIEMENS HEALTHINEERS AG: DEALS 346 TABLE 283 BIOXCEL THERAPEUTICS, INC.: COMPANY OVERVIEW 347 TABLE 284 BIOXCEL THERAPEUTICS, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 347 TABLE 285 BIOXCEL THERAPEUTICS, INC.: DEALS 348 TABLE 286 BIOXCEL THERAPEUTICS, INC.: OTHER DEVELOPMENTS 348 TABLE 287 INSILICO MEDICINE: COMPANY OVERVIEW 349 TABLE 288 INSILICO MEDICINE: PRODUCTS/SERVICES/SOLUTIONS OFFERED 350 TABLE 289 INSILICO MEDICINE: PRODUCT LAUNCHES 350 TABLE 290 INSILICO MEDICINE: DEALS 352 TABLE 291 INSILICO MEDICINE: OTHER DEVELOPMENTS 356 TABLE 292 PATHAI, INC.: COMPANY OVERVIEW 358 TABLE 293 PATHAI, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 359 TABLE 294 PATHAI, INC.: PRODUCT LAUNCHES 360 TABLE 295 PATHAI, INC.: DEALS 362 TABLE 296 PATHAI, INC.: OTHER DEVELOPMENTS 364 TABLE 297 VERGE GENOMICS: COMPANY OVERVIEW 365 TABLE 298 VERGE GENOMICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED 365 TABLE 299 VERGE GENOMICS: DEALS 366 TABLE 300 GUARDANT HEALTH, INC.: COMPANY OVERVIEW 367 TABLE 301 GUARDANT HEALTH, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 368 TABLE 302 GUARDANT HEALTH, INC.: PRODUCT LAUNCHES 369 TABLE 303 GUARDANT HEALTH, INC.: DEALS 370 TABLE 304 GUARDANT HEALTH, INC.: OTHER DEVELOPMENTS 372 TABLE 305 GRAIL, INC.: COMPANY OVERVIEW 374 TABLE 306 GRAIL, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 374 TABLE 307 GRAIL, INC.: DEALS 375 TABLE 308 FOUNDATION MEDICINE, INC.: COMPANY OVERVIEW 377 TABLE 309 FOUNDATION MEDICINE, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 377 TABLE 310 FOUNDATION MEDICINE, INC.: DEALS 378 TABLE 311 FOUNDATION MEDICINE, INC.: OTHER DEVELOPMENTS 380 TABLE 312 PROSCIA INC.: COMPANY OVERVIEW 382 TABLE 313 PROSCIA INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 382 TABLE 314 PROSCIA INC.: PRODUCT LAUNCHES 383 TABLE 315 PROSCIA INC.: DEALS 383 TABLE 316 PROSCIA INC.: OTHER DEVELOPMENTS 384 TABLE 317 FLATIRON HEALTH: COMPANY OVERVIEW 385 TABLE 318 FLATIRON HEALTH: PRODUCTS/SERVICES/SOLUTIONS OFFERED 385 TABLE 319 FLATIRON HEALTH: DEALS 386 TABLE 320 FLATIRON HEALTH: OTHER DEVELOPMENTS 387 TABLE 321 PREDICTIVE ONCOLOGY: COMPANY OVERVIEW 388 TABLE 322 PAIGE AI, INC.: COMPANY OVERVIEW 389 TABLE 323 DENSITAS INC.: COMPANY OVERVIEW 390 TABLE 324 ZEPHYR AI, INC.: COMPANY OVERVIEW 391 TABLE 325 NUCLEAI, INC.: COMPANY OVERVIEW 392 _ FIGURE 1 AI IN PRECISION MEDICINE MARKET SEGMENTATION & REGIONAL SCOPE 33 FIGURE 2 STUDY YEARS CONSIDERED 36 FIGURE 3 RESEARCH DESIGN 38 FIGURE 4 PRIMARY SOURCES 41 FIGURE 5 INSIGHTS FROM PRIMARY EXPERTS 43 FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE), BY COMPANY TYPE, DESIGNATION, AND REGION 43 FIGURE 7 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 44 FIGURE 8 TOP-DOWN APPROACH 45 FIGURE 9 CAGR PROJECTIONS, BY MARKET DYNAMIC, 2024–2030 46 FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 47 FIGURE 11 DATA TRIANGULATION 48 FIGURE 12 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION, 2024 VS. 2030 (USD MILLION) 51 FIGURE 13 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA, 2024 VS. 2030 (USD MILLION) 52 FIGURE 14 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT, 2024 VS. 2030 (USD MILLION) 52 FIGURE 15 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY TOOL, 2024 VS. 2030 (USD MILLION) 53 FIGURE 16 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT, 2024 VS. 2030 (USD MILLION) 54 FIGURE 17 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2024 VS. 2030 (USD MILLION) 54 FIGURE 18 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: GEOGRAPHICAL SNAPSHOT 55 FIGURE 19 GROWING FOCUS ON COST-EFFECTIVE PROCESSES AND FAVORABLE GOVERNMENT SUPPORT AND FUNDING TO DRIVE MARKET 57 FIGURE 20 NORTH AMERICA TO DOMINATE AI IN PRECISION MEDICINE MARKET DURING FORECAST PERIOD 58 FIGURE 21 PHARMACEUTICAL COMPANIES IN NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE IN 2023 59 FIGURE 22 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 60 FIGURE 23 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD 60 FIGURE 24 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 61 FIGURE 25 APPROVAL RATE OF PERSONALIZED MEDICINES BY US FDA, 2015–2023 67 FIGURE 26 HEALTH SECURITY BREACHES, 2009–2023 68 FIGURE 27 INDIVIDUALS AFFECTED BY HEALTHCARE SECURITY BREACHES, 2009–2023 (MILLION) 69 FIGURE 28 USE CASES FOR PREDICTIVE ANALYTICS IN HEALTHCARE 72 FIGURE 29 REVENUE SHIFT IN AI IN PRECISION MEDICINE MARKET 75 FIGURE 30 AI IN PRECISION MEDICINE MARKET: ECOSYSTEM ANALYSIS 77 FIGURE 31 AI IN PRECISION MEDICINE MARKET: VALUE CHAIN ANALYSIS, 2023 79 FIGURE 32 AI IN PRECISION MEDICINE MARKET: PORTER’S FIVE FORCES ANALYSIS 95 FIGURE 33 JURISDICTION ANALYSIS: TOP PATENT APPLICANT COUNTRIES, JANUARY 2015–NOVEMBER 2024 98 FIGURE 34 KEY PATENTS IN AI IN PRECISION MEDICINE MARKET, JANUARY 2015– NOVEMBER 2024 99 FIGURE 35 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS 102 FIGURE 36 KEY BUYING CRITERIA FOR END USERS 103 FIGURE 38 MARKET POTENTIAL OF AI/GENERATIVE AI IN ENHANCING AI IN PRECISION MEDICINE ACROSS INDUSTRIES 111 FIGURE 39 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 113 FIGURE 40 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET SNAPSHOT 183 FIGURE 41 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET SNAPSHOT 218 FIGURE 42 REVENUE ANALYSIS OF KEY PLAYERS, 2019–2023 (USD MILLION) 264 FIGURE 43 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2023 265 FIGURE 44 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: RANKING OF KEY PLAYERS, 2023 267 FIGURE 45 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 269 FIGURE 46 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: COMPANY FOOTPRINT, 2023 270 FIGURE 47 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 277 FIGURE 48 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024 279 FIGURE 49 EV/EBITDA OF KEY VENDORS, 2024 280 FIGURE 50 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 281 FIGURE 51 NVIDIA CORPORATION: COMPANY SNAPSHOT 288 FIGURE 52 EXSCIENTIA: COMPANY SNAPSHOT 297 FIGURE 53 GOOGLE: COMPANY SNAPSHOT 308 FIGURE 54 ILLUMINA, INC.: COMPANY SNAPSHOT 314 FIGURE 55 BENEVOLENTAI: COMPANY SNAPSHOT 325 FIGURE 56 MICROSOFT CORPORATION: COMPANY SNAPSHOT 330 FIGURE 57 IBM: COMPANY SNAPSHOT 335 FIGURE 58 GE HEALTHCARE: COMPANY SNAPSHOT 338 FIGURE 59 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT 345 FIGURE 60 GUARDANT HEALTH: COMPANY SNAPSHOT 368